bluuebunny/crossref_metadata_2025_split huggingface dataset:
Nonoperative management of blunt renal trauma: Is routine early follow-up imaging necessary?
Authors: Malcolm John B , Derweesh Ithaar H , Mehrazin Reza , DiBlasio Christopher J , Vance David D , Joshi Salil , Wake Robert W , Gold Robert 
Published: September 2008

Abstract

Background
There is no consensus on the role of routine follow-up imaging during nonoperative management of blunt renal trauma. We reviewed our experience with nonoperative management of blunt renal injuries in order to evaluate the utility of routine early follow-up imaging.

Methods
We reviewed all cases of blunt renal injury admitted for nonoperative management at our institution between 1/2002 and 1/2006. Data were compiled from chart review, and clinical outcomes were correlated with CT imaging results.

Results
207 patients were identified (210 renal units). American Association for the Surgery of Trauma (AAST) grades I, II, III, IV, and V were assigned to 35 (16%), 66 (31%), 81 (39%), 26 (13%), and 2 (1%) renal units, respectively. 177 (84%) renal units underwent routine follow-up imaging 24–48 hours after admission. In three cases of grade IV renal injury, a ureteral stent was placed after serial imaging demonstrated persistent extravasation. In no other cases did follow-up imaging independently alter clinical management. There were no urologic complications among cases for which follow-up imaging was not obtained.

Conclusion
Routine follow-up imaging is unnecessary for blunt renal injuries of grades I-III. Grade IV renovascular injuries can be followed clinically without routine early follow-up imaging, but urine extravasation necessitates serial imaging to guide management decisions. The volume of grade V renal injuries in this study is not sufficient to support or contest the need for routine follow-up imaging.
Understanding ageing: Biomedical and bioengineering approaches, the immunologic view
Authors: Bulati Matteo , Pellicanò Mariavaleria , Vasto Sonya , Colonna-Romano Giuseppina 
Published: September 2008

Abstract
During the past century, humans have gained more years of average life expectancy than in the last 10,000 years; we are now living in a rapidly ageing world. The sharp rise in life expectancy, coupled to a steady decline in birth rates in all developed countries, has led to an unprecedented demographic revolution characterized by an explosive growth in the number and proportion of older people. Ageing is a complex process that negatively impacts the development of the immune system and its ability to function. Progressive changes in the T and B cell systems over the life span have a major impact on the capacity to respond to immune challenge. These cumulative age-associated changes in immune competence are termed Immunosenescence: some immunological parameters are commonly notably reduced in the elderly and, reciprocally good function is tightly correlated to health status. Hence, a better understanding of Immunosenescence and the development of new strategies to counteract it are essential for improving the quality of life of the elderly population.
Accelerometer-based wireless body area network to estimate intensity of therapy in post-acute rehabilitation
Authors: Choquette Stéphane , Hamel Mathieu , Boissy Patrick 
Published: September 2008

Abstract

Background
It has been suggested that there is a dose-response relationship between the amount of therapy and functional recovery in post-acute rehabilitation care. To this day, only the total time of therapy has been investigated as a potential determinant of this dose-response relationship because of methodological and measurement challenges. The primary objective of this study was to compare time and motion measures during real life physical therapy with estimates of active time (i.e. the time during which a patient is active physically) obtained with a wireless body area network (WBAN) of 3D accelerometer modules positioned at the hip, wrist and ankle. The secondary objective was to assess the differences in estimates of active time when using a single accelerometer module positioned at the hip.

Methods
Five patients (77.4 ± 5.2 y) with 4 different admission diagnoses (stroke, lower limb fracture, amputation and immobilization syndrome) were recruited in a post-acute rehabilitation center and observed during their physical therapy sessions throughout their stay. Active time was recorded by a trained observer using a continuous time and motion analysis program running on a Tablet-PC. Two WBAN configurations were used: 1) three accelerometer modules located at the hip, wrist and ankle (M3) and 2) one accelerometer located at the hip (M1). Acceleration signals from the WBANs were synchronized with the observations. Estimates of active time were computed based on the temporal density of the acceleration signals.

Results
A total of 62 physical therapy sessions were observed. Strong associations were found between WBANs estimates of active time and time and motion measures of active time. For the combined sessions, the intraclass correlation coefficient (ICC) was 0.93 (P ≤ 0.001) for M3 and 0.79 (P ≤ 0.001) for M1. The mean percentage of differences between observation measures and estimates from the WBAN of active time was -8.7% ± 2.0% using data from M3 and -16.4% ± 10.4% using data from M1.

Conclusion
WBANs estimates of active time compare favorably with results from observation-based time and motion measures. While the investigation on the association between active time and outcomes of rehabilitation needs to be studied in a larger scale study, the use of an accelerometer-based WBAN to measure active time is a promising approach that offers a better overall precision than methods relying on work sampling. Depending on the accuracy needed, the use of a single accelerometer module positioned on the hip may still be an interesting alternative to using multiple modules.
Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions
Authors: Parente Paola , Coli Antonella , Massi Guido , Mangoni Antonella , Fabrizi Manuela M , Bigotti Giulio 
Published: September 2008

Abstract

Background
Reported data indicate that cancer cells have increased rates of glucose metabolism, as determined by 18FDG-PET imaging in patients with malignancies. The results of many studies have demonstrated that the expression of glucose transporters, especially Glut-1, is increased in a variety of malignancies. This study was undertaken to assess the differential expression of Glut-1 and Glut-3 by benign and malignant melanocytic lesions.

Methods
Immunohistochemical staining for Glut-1 and Glut-3 was performed on paraffin-embedded tissue sections prepared from melanocytic nevi (12 cases), Spitz nevi (12 cases) and primary cutaneous malignant melanomas (20 cases).

Results
We observed immunoreactivity for Glut-1 in all melanocytic nevi, 9 of the 12 Spitz nevi and in 9 of the 20 malignant melanomas, whereas Glut-3 was expressed in all the melanocytic lesions, both benign and malignant.

Conclusion
These findings indicate that the glucose transporters Glut-1 and Glut-3 play a role in the glucose metabolism of melanocytic cells. Glut-1 was present in the majority of benign nevi, whereas its expression was downregulated in 55% of malignant melanomas. Our results suggest that glucose transporter Glut-1 expression can significantly discriminate between human malignant melanoma and benign melanocytic nevi, and support the idea that additional mechanisms other than Glut-1 may contribute to glucose uptake in melanomas.
Vertebral artery dissection presenting with ispilateral acute C5 and C6 sensorimotor radiculopathy: A case report
Authors: Tabatabai Ghazaleh , Schöber Wolfgang , Ernemann Ulrike , Weller Michael , Krüger Rejko 
Published: September 2008

Abstract
Spinal manifestations of vertebral artery dissection (VAD) are rare events and are typically symptomatic with neck pain and ischemic brain injury. We report a patient presenting with unusual peripheral paresis of the right upper limb due to an intramural hematoma of the right vertebral artery with local compression of C5 and C6 as the cause of cervical radiculopathy. These symptoms completely resolved after anticoagulation and physical therapy.
Interleukin-6 acts in the fashion of a classical chemokine on monocytic cells by inducing integrin activation, cell adhesion, actin polymerization, chemotaxis, and transmigration
Authors: Clahsen Thomas , Schaper Fred 
Published: September 2008

AbstractMacrophages contribute to the innate immune response by eliminating bacteria, viral particles, and apoptotic bodies. They develop from circulating monocytes. In case of an infection, monocytes attach to the endothelial cells of the blood vessels, migrate along the endothelial cells, leave the circulatory system to enter the inflammatory tissue, and differentiate into macrophages. Cell migration is induced frequently by chemokines that act through G-protein-coupled receptors. Only a few cytokines signaling through single-transmembrane domain receptors have been shown to induce cell migration. Often, this potential depends on the induction of classical chemokines and is not a direct cellular effect. Here, we discovered IL-6 as a potent stimulant for monocytic cell migration. Furthermore, we present data about IL-6-induced integrin activation, cell attachment, actin polymerization, fibronectin-dependent migration, and transmigration through a layer of endothelial cells. Our results show that IL-6 fulfills all biological properties to mediate cell migration of monocytic cells, which may contribute to the proinflammatory potential of IL-6.
Normal mouse kidneys contain activated and CD3+CD4−CD8− double-negative T lymphocytes with a distinct TCR repertoire
Authors: Ascon Dolores B , Ascon Miguel , Satpute Shailesh , Lopez-Briones Sergio , Racusen Lorraine , Colvin Robert B , Soloski Mark J , Rabb Hamid 
Published: September 2008

AbstractHealthy liver, intestine, lung, and skin harbor resident lymphocytes with conventional and unconventional phenotypes. Lymphocytes also have been detected in healthy mice kidneys; however, these cells have not been well studied and have been largely overlooked. To better characterize the intra-renal lymphocytes, we extensively perfused C57BL/6J mice with PBS and then isolated mononuclear cells for flow cytometry analysis. We observed T cells, B cells, and NK cells in normal mice kidneys after extensive perfusion. Approximately 50% of kidney T lymphocytes expressed intermediate levels of CD3 (CD3int T cells). Similar to liver and lung, a high percentage of unconventional CD3+CD4−CD8− double-negative T cells was observed in normal mice kidneys, from which 11% expressed B220 antigen. Unlike the spleen and blood, the classic CD4+ and CD8+ T lymphocytes in the kidney had a high proportion of activated CD69+ and effector/memory CD44CD62L ligand phenotypes. Also, a small percentage of CD4+CD25+forkhead box p3+ and NKT cells was observed in perfused and exanguinated kidneys. In addition, a distinct TCR repertoire was found on intra-renal conventional and unconventional T cells compared with those from the spleen. Finally, after 24 h of renal ischemia reperfusion injury (IRI), increased production of cytokines IFN-γ and TNF-α by CD4+ and CD8+ T cells, isolated from perfused kidneys, was observed. These data suggest that some of these cells harbored in the kidney could be implicated in the immune response of the IRI pathogenic process.
Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
Authors: Bartlett John M.S. , Munro Alison , Cameron David A. , Thomas Jeremy , Prescott Robin , Twelves Chris J. 
Published: September 2008

PurposePatients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non–anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIα expression are predictive of outcome after anthracycline-based chemotherapy.MethodsTissue microarrays from 322 of 374 women in the BR9601 trial, which compared cyclophosphamide, methotrexate, and fluorouracil (CMF) with epirubicin followed by CMF (epi-CMF), were analyzed for HER1, 2, 3, 4; Ki67; and topoisomerase IIα protein expression and for HER2/topoisomerase IIα gene amplification. Their relationships to RFS and OS were investigated, and multiple regression analysis was used to identify interactions.ResultsA significant interaction was seen between tumors with normal HER1, HER2 fluorescent in situ hybridization (FISH), or HER3 levels and the enhanced benefit from epi-CMF versus CMF for RFS (hazard ratio [HR], 0.36; HR for overexpressed HER1 or HER2 FISH or HER3, 0.92; P = .035) and for OS (HR, 0.30; HR for overexpressed HER1 or HER2 FISH or HER3), 0.98; P = .023). Neither Ki67 nor TIIα expressions or gene alterations showed clear predictive value for benefit from the addition of the anthracycline.ConclusionPatients with HER2 amplified and those with HER1, HER2 FISH, or HER3-positive tumors did not benefit from the addition of epirubicin to CMF. Conversely, patients with HER2 nonamplified and HER1 through HER3–negative tumors showed significantly increased RFS and OS rates when treated with epi-CMF compared with CMF.
Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group
Authors: Schetelig Johannes , Bornhäuser Martin , Schmid Christoph , Hertenstein Bernd , Schwerdtfeger Rainer , Martin Hans , Stelljes Matthias , Hegenbart Ute , Schäfer-Eckart Kerstin , Füssel Monika , Wiedemann Barbel , Thiede Christian , Kienast Joachim , Baurmann Herrad , Ganser Arnold , Kolb Hans Jochem , Ehninger Gerhard 
Published: September 2008

Purpose In patients with acute myeloid leukemia (AML), differential indications for matched sibling and unrelated hematopoietic stem-cell transplantation (HCT) are considered, and arbitrary age limits for HCT exist. We sought to determine whether donor type is a prognostic factor in elderly patients in the era of high-resolution DNA-based HLA typing. Patients and Methods We performed univariate and multivariate analyses of event-free survival (EFS) and overall survival (OS) in patients older than 50 years with standard- or high-risk AML who had received an allogeneic HCT between 1995 and 2005. Available DNA from donors and recipients of unrelated HCT was retyped so that the HLA-A, -B, -C, and -DRB1 alleles could be characterized in detail. Unrelated donors (UDs) were classified as matched (8/8), possibly matched (matched, but incomplete information), partially matched (one mismatch), or poorly matched (two or more mismatches) according to the final typing results. Results Data from 368 patients with a median age of 57 years (range, 50 to 73 years) were included. Multivariate Cox regression analysis revealed that patients’ disease status at HCT (P < .001) and the cytogenetic risk (P < .001) highly significantly predicted EFS and OS. Compared with patients with matched sibling donors, the adjusted relative risk of EFS was 0.7 (95% CI, 0.4 to 1.1) for patients with matched UDs and 1.0 (95% CI, 0.7 to 1.6) for patients with partially matched UDs. Conclusion Donor type is not a major prognostic factor for HCT in elderly patients with standard- or high-risk AML.
Somatic CEBPA Mutations Are a Frequent Second Event in Families With Germline CEBPA Mutations and Familial Acute Myeloid Leukemia
Authors: Pabst Thomas , Eyholzer Marianne , Haefliger Simon , Schardt Julian , Mueller Beatrice U. 
Published: September 2008

Purpose The transcription factor CCAAT/enhancer binding protein-α (CEBPA) is crucial for normal myeloid differentiation. Mutations in the CEBPA gene are found in subsets of patients with acute myeloid leukemia (AML). Recently, three families were reported in whom several family members had germline CEBPA mutations and subsequently developed AML. Whereas familial AML is considered a rare event, the frequency of CEBPA germline mutations in AML is not known. Patients and Methods In this study, we screened 187 consecutive AML patients for CEBPA mutations at diagnosis. We detected 18 patients (9.6%) with CEBPA mutations. We then analyzed remission samples and constitutive DNA from these patients. Results We found that two (11.1%) of 18 AML patients with CEBPA mutations carried a germline N-terminal frameshift CEBPA mutation. Interestingly, additional members in the families of both of these patients have been affected by AML, and the germline CEBPA mutations were also observed in these patients. Additional somatic mutations in AML patients with germline CEBPA mutations in the two families comprised in-frame C-terminal CEBPA mutations in two patients, two nonsilent CEBPA point mutations in one patient, and monosomy 7 in one patient. Conclusion This study shows, for the first time to our knowledge, that germline CEBPA mutations are frequently observed among AML patients with CEBPA mutations. Including the families with germline CEBPA mutations reported previously, additional somatic CEBPA mutations represent a frequent second event in AML with germline CEBPA mutations. Our data strongly indicate that germline CEBPA mutations predispose to AML and that additional somatic CEBPA mutations contribute to the development of the disease.
Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA
Authors: Martenson James A. , Halyard Michele Y. , Sloan Jeff A. , Proulx Gary M. , Miller Robert C. , Deming Richard L. , Dick Stephen J. , Johnson Harold A. , Tai T.H. Patricia , Zhu Angela W. , Keit Joan , Stien Kathy J. , Atherton Pamela J. 
Published: September 2008

Purpose To assess the effectiveness of depot octreotide for the prevention of diarrhea during pelvic radiation therapy. Patients and Methods Patients receiving pelvic radiation therapy (planned minimum dose, 45 Gy; 1.7 to 2.1 Gy daily) were eligible for the study. From May 10, 2002, through October 14, 2005, 125 patients were randomly allocated in a double-blind fashion to receive octreotide (100 μg, administered subcutaneously on day 1, followed by depot octreotide, 20 mg, administered intramuscularly on days 2 and 29; n = 62) or to receive a placebo (n = 63). Results Grade 0, 1, 2, and 3 diarrhea were observed in 18%, 31%, 31%, and 21% of patients in the octreotide arm, respectively, and in 25%, 32%, 22%, and 21% of patients in the placebo arm, respectively (P = .64). Grade 0, 1, 2, and 3 abdominal cramps were observed in 32%, 45%, 21%, and 2% of patients receiving octreotide, respectively, and in 51%, 24%, 21%, and 5% of patients receiving the placebo, respectively (P = .053). Some patient-reported symptoms were worse in the octreotide group, including nocturnal bowel movements (70% v 45%; P = .004), clustering of bowel movements (90% v 69%; P = .004), and bleeding with bowel movements (57% v 35%; P = .01). Conclusion As administered in this study, octreotide did not decrease diarrhea during pelvic radiation therapy. Some gastrointestinal symptoms were worse in patients treated with octreotide. Octreotide is not indicated for prevention of diarrhea during pelvic radiation therapy.
The Effects of Central Adiposity on Growth Hormone (GH) Response to GH-Releasing Hormone-Arginine Stimulation Testing in Men
Authors: Makimura Hideo , Stanley Takara , Mun David , You Sung Min , Grinspoon Steven 
Published: September 2008

Context: The relative contribution of central adiposity vs. weight on GH response to stimulation testing in obesity is not known.
Objective: We aimed to assess the contribution of weight and specific measures of central and peripheral adiposity to GH response to GHRH-arginine testing in lean, overweight, and obese men.
Design: A total of 75 men [mean age, 44.3 ± 1.1 yr; body mass index (BMI), 28.8 ± 0.7 kg/m2] were investigated. Subjects were classified as lean (BMI &lt; 25 kg/m2; n = 23), overweight (BMI ≥ 25 and &lt;30 kg/m2; n = 28), or obese (BMI ≥ 30 kg/m2; n = 24). Subjects were also stratified by waist circumference (WC) (&lt;102 cm, n = 47; ≥102 cm, n = 28). Body composition and regional adiposity were assessed by anthropometrics, dual-energy x-ray absorptiometry (DEXA), and abdominal computed tomography (CT) scans.
Results: Peak stimulated GH was 36.4 ± 5.4, 16.6 ± 2.9, and 7.6 ± 0.9 μg/liter among lean, overweight, and obese subjects, respectively (P &lt; 0.001 for all comparisons). Peak stimulated GH was 26.9 ± 3.4 μg/liter among subjects with WC less than 102 cm compared to 7.9 ± 0.9 μg/liter among subjects with WC of 102 cm or greater (P &lt; 0.0001). Separate multivariate models using anthropometric, DEXA, and CT-derived measures of central adiposity demonstrated strong associations between peak stimulated GH and measures of central adiposity including WC, trunk fat by DEXA, and visceral adiposity by CT, controlling for age, BMI, and more general measures of adiposity. WC was independently associated with peak GH response to GHRH-arginine in a model including age, BMI, and hip circumference. In this model, BMI was no longer significant, and peak GH was reduced 1.02 μg/liter for each 1 cm increase in WC (P = 0.02).
Conclusions: GH response to GHRH-arginine testing is reduced in both overweight and obese subjects and negatively associated with indices of central abdominal obesity including WC, trunk fat, and visceral adipose tissue. The use of waist circumference, as a surrogate for central adiposity, adds predictive information to the determination of GH response, independent of BMI.
A parametric study of part distortions in fused deposition modelling using three-dimensional finite element analysis
Authors: Zhang Y , Chou K 
Published: September 2008

A finite element analysis (FEA) model was previously developed by the current authors to simulate the fused deposition modelling (FDM) process. The model considered coupled thermal and mechanical phenomena and incorporated an element activation function to mimic the additive nature of FDM. Due to repetitive heating and cooling in the FDM process, residual stresses accumulate in a part during deposition. In this study, an FEA model is used to evaluate the distortions of a part. A parametric study, with three factors and three levels, is performed to evaluate the effects of the deposition parameters on residual stresses and part distortions. Prototype models with larger sizes are fabricated, measured, and compared with the simulations. The simulation results are summarized as follows. First, the scan speed is the most significant factor affecting part distortions, followed by the layer thickness. Second, the road width alone is insignificant. However, the interaction between the road width and the layer thickness is significant as well. Third, there are other two-way and three-way interactions that are of secondary significance. In general, residual stresses in FDM parts increase with the layer thickness. Residual stresses also increase with the road width, but to a lesser extent, although largely affected by the layer thickness. The FDM part distortions from the experiment show a similar trend as concluded in the simulations, but without quantitative correlation.